You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國同輻(01763.HK)中期淨利同比增加48.51%至1.07億元
格隆匯 08-28 01:38

格隆匯8月28日丨中國同輻(01763.HK)公佈,截至2021年6月30日止6個月,公司收益為人民幣20.58億元,同比增加35.61%;公司權益股東應占期內利潤為人民幣1.07億元,同比增加48.51%;每股盈利為人民幣0.33元。

集團主要從事診斷及治療用放射性藥品、醫用和工業用放射源產品的研究、開發、製造及銷售,提供輻照滅菌服務及伽瑪射線輻照裝置的設計、製造及安裝的EPC服務,同時,向醫院及其他醫療機構提供獨立醫學檢驗實驗室服務以及核醫療裝備。

截至2021年6月30日止6個月,我們經營五個業務分部,包括藥品、放射源產品、輻照、獨立醫學檢驗實驗室服務及其他業務,以及放射治療設備及相關服務。

隨着中國經濟社會發展,國內醫療水平提高,核醫學顯像技術的廣泛應用和靶向放射性治療藥物的強大臨牀潛力有力推動了我國放射性藥物的臨牀應用需求。報吿期內,集團乘勢而上,精心組織科研生產活動,全力推進產業戰略佈局和市場開拓。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account